Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Motoi Maeda is active.

Publication


Featured researches published by Motoi Maeda.


Journal of Immunology | 2005

Murine CD160, Ig-Like Receptor on NK Cells and NKT Cells, Recognizes Classical and Nonclassical MHC Class I and Regulates NK Cell Activation

Motoi Maeda; Carmine Carpenito; Ryan C. Russell; Jyoti Dasanjh; Linnea L. Veinotte; Hideaki Ohta; Takashi Yamamura; Rusung Tan; Fumio Takei

Human and mouse NK cells use different families of receptors to recognize MHC class I (MHC I) on target cells. Although human NK cells express both Ig-like receptors and lectin-like receptors specific for MHC I, all the MHC I-specific receptors identified on mouse NK cells to date are lectin-like receptors, and no Ig-like receptors recognizing MHC I have been identified on mouse NK cells. In this study we report the first MHC I-specific Ig-like receptor on mouse NK cells, namely, murine CD160 (mCD160). The expression of mCD160 is restricted to a subset of NK cells, NK1.1+ T cells, and activated CD8+ T cells. The mCD160-Ig fusion protein binds to rat cell lines transfected with classical and nonclassical mouse MHC I, including CD1d. Furthermore, the level of mCD160 on NK1.1+ T cells is modulated by MHC I of the host. Overexpression of mCD160 in the mouse NK cell line KY-2 inhibits IFN-γ production induced by phorbol ester plus ionomycin, whereas it enhances IFN-γ production induced by NK1.1 cross-linking or incubation with dendritic cells. Cross-linking of mCD160 also inhibits anti-NK1.1-mediated stimulation of KY-2 cells. Anti-mCD160 mAb alone has no effect. Thus, mCD160, the first MHC I-specific Ig-like receptor on mouse NK cells, regulates NK cell activation both positively and negatively, depending on the stimulus.


Leukemia Research | 1999

Correlation of telomerase activity with development and progression of adult T-cell leukemia.

Naoyuki Uchida; Teruhisa Otsuka; Fumitou Arima; Hirokazu Shigematsu; Tomofusa Fukuyama; Motoi Maeda; Yasuhiro Sugio; Yoshikiyo Itoh; Yoshiyuki Niho

Telomerase is an enzyme that adds hexameric TTAGGG nucleotide repeats to the ends of vertebrate chromosomal DNAs (i.e. telomeres) to compensate for losses that occur with each round of DNA replication. Telomerase activity, demonstrable in most human tumors, enables them to maintain telomere stability. Peripheral blood mononuclear cells were sampled from 57 patients seropositive for human T-lymphotropic virus type I (HTLV-I), including 24 asymptomatic viral carriers, ten smoldering type, five chronic type, and 18 acute type adult T-cell leukemia (ATL). Telomerase activity was determined in samples using a modified telomeric repeat amplification protocol. We semiquantitatively determined telomerase activity by serial dilution of each sample. All of 23 samples from acute and chronic type ATL patients were positive, seven of ten (70%) smoldering type patients and seven of 24 (29.2%) asymptomatic viral carriers were positive. Disease progression from asymptomatic viral carrier to acute type correlated with telomerase activity. Two samples from chronic type ATL patients with relatively high telomerase activity progressed to the acute type within 1 month. Serum lactate dehydrogenase level also correlated with telomerase activity. These results indicate that reactivation of telomerase activity is a key event in development and progression of ATL, and telomerase could be a useful marker for predicting the course of disease. Accordingly, ATL could be a good candidate disease for trials of telomerase inhibitors, as novel anticancer drugs.


Journal of Immunology | 2004

CD1d-Independent NKT Cells in β2-Microglobulin-Deficient Mice Have Hybrid Phenotype and Function of NK and T Cells

Motoi Maeda; Ashleen Shadeo; Anna M. MacFadyen; Fumio Takei

Unlike CD1d-restricted NK1.1+TCRαβ+ (NKT) cells, which have been extensively studied, little is known about CD1d-independent NKT cells. To characterize their functions, we analyzed NKT cells in β2-microglobulin (β2m)-deficient B6 mice. They are similar to NK cells and expressed NK cell receptors, including Ly49, CD94/NKG2, NKG2D, and 2B4. NKT cells were found in normal numbers in mice that are deficient in β2m, MHC class II, or both. They were also found in the male HY Ag-specific TCR-transgenic mice independent of positive or negative selection in the thymus. For functional analysis of CD1d-independent NKT cells, we developed a culture system in which CD1d-independent NKT cells, but not NK, T, or most CD1d-restricted NKT cells, grew in the presence of an intermediate dose of IL-2. IL-2-activated CD1d-indpendent NKT cells were similar to IL-2-activated NK cells and efficiently killed the TAP-mutant murine T lymphoma line RMA-S, but not the parental RMA cells. They also killed β2m-deficient Con A blasts, but not normal B6 Con A blasts, indicating that the cytotoxicity is inhibited by MHC class I on target cells. IL-2-activated NKT cells expressing transgenic TCR specific for the HY peptide presented by Db killed RMA-S, but not RMA, cells. They also killed RMA (H-2b) cells that were preincubated with the HY peptide. NKT cells from β2m-deficient mice, upon CD3 cross-linking, secreted IFN-γ and IL-2, but very little IL-4. Thus, CD1d-independent NKT cells are significantly different from CD1d-restricted NKT cells. They have hybrid phenotypes and functions of NK cells and T cells.


Leukemia Research | 1999

Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells

Naoyuki Uchida; Teruhisa Otsuka; Hirokazu Shigematsu; Motoi Maeda; Yasuhiro Sugio; Yoshikiyo Itoh; Yoshiyuki Niho

The maintenance of telomere length is crucial for the survival of cells. Recently, genes for proteins that consist of human telomerase have been cloned and the results have indicated a close relationship between telomerase activity and its gene expression. We studied the mRNA expression of the telomerase-associated genes, hTERT and TEP1, in hematopoietic cells in order to clarify the relation between them and telomerase activity using semiquantitative RT-PCR. In polymorphonuclear cells and monocytes isolated from peripheral blood, which had no detectable telomerase activity, no hTERT mRNA expression was seen. On the other hand, lymphocytes and CD34-positive cells both demonstrated hTERT mRNA expression. TEP1 mRNA was detected in all samples, showing no differential expression. We then assessed hTERT and TEP1 mRNA expression in CD34-positive cells cultured in vitro with growth factors. After 4 weeks of culture, all the cells showed myeloid differentiation and the telomerase activity was downregulated. hTERT mRNA was expressed in CD34-positive cells, but was downregulated in 4-week-cultured cells. TEP1 showed no apparent differential expression. We conclude that hTERT mRNA expression is downregulated in accordance with telomerase downregulation during the course of myeloid differentiation, which suggests that it plays a crucial role in the expression of enzyme activity, while TEP1 has a much smaller role to play, if any.


British Journal of Haematology | 2000

Induction of MTG8‐specific cytotoxic T‐cell lines: MTG8 is probably a tumour antigen that is recognized by cytotoxic T cells in AML1–MTG8‐fused gene‐positive acute myelogenous leukaemia

Motoi Maeda; Teruhisa Otsuka; Nobuhiro Kimura; Tomoko Kozu; Tomofusa Fukuyama; Naoyuki Uchida; Yasuhiro Sugio; Yoshikiyo Itoh; Tadafumi Iino; Shoichi Inaba; Yoshiyuki Niho

Several reports have demonstrated the persistent detection of AML1–MTG8 fusion products, representing minimal residual disease (MRD), in patients with t(8;21) acute myelogenous leukaemia (AML) who are in long‐term remission. It is probable that immune‐mediated mechanisms that are able to suppress the expansion of MRD may result in the continuance of remission. It was previously shown that some t(8;21) AML patients had high anti‐MTG8 antibody titres. MTG8 expression in normal adult tissues is limited to the brain or heart in which human leucocyte antigen (HLA) class I cell‐surface antigens are either not or are only faintly detectable. We hypothesized that the overexpression of the MTG8 gene in t(8;21) AML cells could act as a possible tumour antigen, which might be able to induce the immune‐mediated suppression of the expansion of MRD. We were able to induce HLA‐A0201‐restricted cytotoxic T‐lymphocyte (CTL) lines against an MTG8 peptide (MTG8b amino acids 182–191) using monocyte‐derived dendritic cells from a healthy donor. T‐cell receptor (TCR)Vα17, TCRVβ14 and 15, and TCRJβ2.1 and 2.3 are predominantly used in these CTL lines. Our data, which suggest that the MTG8 protein could be one of the tumour antigens recognized by CTLs, may be helpful in further investigations of TCR analysis in t(8;21) AML patients with HLA‐A0201 who are in long‐term remission.


Leukemia & Lymphoma | 2000

Vaccination of a refractory essential monoclonal cryoglobulinemia patient with cryoglobulin-pulsed dendritic cells

Motoi Maeda; Shoichi Inaba; Akihiko Nomura; Yasunobu Tokunaga; Yasuhiro Sugio; Yoshikiyo Itoh; Tadafumi Iino; Teruhisa Otsuka; Seiichi Okamura; Yoshiyuki Niho

We vaccinated a refractory essential monoclonal cryoglobulinemia patient with monocyte-derived DCs (Mo-DCs) pulsed with purified cryoglobulin as a tumor antigen. During the vaccinations, his acrocyanosis improved and we were able to reduce the number of hot baths used to treat his symptoms, with no sick effects. Furthermore, cryoglobulin-specific proliferative responses were observed after the vaccination. As there wax a recurrence of acrocyanosis after the final vaccination, vaccination with Mo-DCs pulsed with purified cryoglobulin would seem to be a useful treatment for refractory essential monoclonal cryoglobulinemia.


Biomedicine & Pharmacotherapy | 2001

Intracellular cytokine profile of CD14 positive cells in patients with hematologic malignancies and solid tumors during hematologic recovery phase after intensive chemotherapy designed to mobilize peripheral blood stem cells.

Motoi Maeda; Yasunobu Tokunaga; Akihiko Nomura; Shoichi Inaba; Yasuhiro Sugio; Yoshikiyo Itoh; Tadafumi Iino; Teruhisa Otsuka; Yoshiyuki Niho

We studied intracellular cytokines in monocytes by flow cytometry from 28 patients with hematologic malignancies and solid tumors to analyze the role of monokines in the hematologic recovery phase for peripheral blood stem cell harvest. The patients were divided into three groups: the first group, A, had a documented infection; the second group, B, had fever of unknown origin; and the third group, C, was afebrile. We found an increase in intracellular IL-1alpha, IL-6, IL-8 and TNF-alpha positive monocytes as CD14 positive gated cells cultured with lipopolysaccharide in all groups, but no increase was found with medium only when cultured for 4 h. We also found an increase in intracellular IL-1a, IL-6, IL-8 and TNF-alpha positive monocytes cultured with autologous serum for 4 h, but only in group A. The rate of intracellular cytokine positive cells was higher in monocytes cultured with only autologous serum from group A patients compared to those cells from the other groups; the data concerning IL-1a, IL-6 and TNF-alpha reached statistical significance (P < 0.05). However, increasing intracellular cytokine levels in the control group of patients exhibiting only infectious disease were observed. Thus, it appear that pro-inflammatory intracellular cytokine levels in monocytes are only related to microbial infections.


Experimental Hematology | 2003

Slow receptor acquisition by NK cells regenerated in vivo from transplanted fetal liver or adult bone marrow stem cells

Motoi Maeda; Naoyuki Uchida; Connie J. Eaves; Fumio Takei


Leukemia Research | 2004

Growth and apoptosis of human natural killer cell neoplasms: role of interleukin-2/15 signaling

Satoshi Yamasaki; Motoi Maeda; Koichi Ohshima; Masahiro Kikuchi; Teruhisa Otsuka; Mine Harada


International Journal of Hematology | 2000

Down-regulation of human telomeric protein TRF1 gene expression during myeloid differentiation in human hematopoietic cells.

Teruhisa Otsuka; Naoyuki Uchida; Fumitou Arima; Hirokazu Shigematsu; Tomofusa Fukuyama; Motoi Maeda; Yasuhiro Sugio; Yoshikiyo Itoh; Yoshiyuki Niho

Collaboration


Dive into the Motoi Maeda's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fumio Takei

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge